| sess_SDA-2026-04-06- | The abstract identifies dystrophic microglia as senescent cells in aged brains b | 0.79 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041439-5f43216e |
| sess_SDA-2026-04-06- | Multiple hypotheses assumed microglia could be restored to homeostatic states, b | 0.63 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-7a6cf14e |
| sess_SDA-2026-04-06- | While DNAJB1 enhancement showed promise, the debate raised concerns about whethe | 0.73 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062052-28cbc764 |
| sess_SDA-2026-04-06- | The debate identified APOE4 astrocytes as potential senescence drivers but did n | 0.76 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062101-5d7b9dc0 |
| sess_SDA-2026-04-06- | The abstract indicates SPP1 upregulation occurs in perivascular macrophages and | 0.67 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-062118-5e49e14f |
| target_debate_target | Should ANXA1 (Annexin A1) be prioritized as a therapeutic target for neurodegene | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should FOXO3 (Forkhead box protein O3) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should ABCA1 (ATP-binding cassette transporter A1) be prioritized as a therapeut | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should ANGPT1 (Angiopoietin-1) be prioritized as a therapeutic target for neurod | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should HDAC3 (Histone Deacetylase 3) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should SRPK1 (SRSF protein kinase 1) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should EPHB4 (Ephrin type-B receptor 4) be prioritized as a therapeutic target f | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should ALOX5 (5-lipoxygenase) be prioritized as a therapeutic target for neurode | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should GPX4 (Glutathione peroxidase 4) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should GPR37 (G-protein coupled receptor 37) be prioritized as a therapeutic tar | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should DNMT1 (DNA methyltransferase 1) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should BACE1 (Beta-secretase 1) be prioritized as a therapeutic target for neuro | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should STING1 (Stimulator of interferon genes protein 1) be prioritized as a the | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should PPARGC1A (Peroxisome proliferator-activated receptor gamma coactivator 1- | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should CASP1 (Caspase-1) be prioritized as a therapeutic target for neurodegener | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should MMP2 (Matrix metalloproteinase-2) be prioritized as a therapeutic target | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should HCN1 (Hyperpolarization-activated cyclic nucleotide-gated potassium chann | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should PRMT1 (Protein arginine methyltransferase 1) be prioritized as a therapeu | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should SOAT1 (Sterol O-acyltransferase 1) be prioritized as a therapeutic target | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should MIRO1 (Mitochondrial Rho GTPase 1) be prioritized as a therapeutic target | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should TFAM (Transcription factor A, mitochondrial) be prioritized as a therapeu | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should TNFA (Tumor necrosis factor alpha) be prioritized as a therapeutic target | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should GJA1 (Gap junction alpha-1 protein (Connexin 43)) be prioritized as a the | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should FOXO1 (Forkhead box protein O1) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should TFRC (Transferrin receptor protein 1) be prioritized as a therapeutic tar | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should TLR4 (Toll-like receptor 4) be prioritized as a therapeutic target for ne | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should STX17 (Syntaxin-17) be prioritized as a therapeutic target for neurodegen | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should TUBB3 (Tubulin beta-3 chain) be prioritized as a therapeutic target for n | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should TET2 (Tet methylcytosine dioxygenase 2) be prioritized as a therapeutic t | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | The study shows trehalose causes lysosomal membrane permeabilization (LMP) that | 0.61 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062150-a6cc7467 |
| target_debate_target | Should NR3C1 (Glucocorticoid receptor) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should MMP9 (Matrix metalloproteinase-9) be prioritized as a therapeutic target | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | While SPP1 absence prevents synaptic loss, it's unclear whether this represents | 0.69 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062118-2cdbb0dd |
| target_debate_target | Should FKBP5 (FKBP prolyl isomerase 5) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | The study shows that G3BP1 ubiquitination inhibits LLPS in vitro, but the molecu | 0.79 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041423-2d1db50c |
| target_debate_target | Should BDNF (Brain Derived Neurotrophic Factor) be prioritized as a therapeutic | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should C1Q (Complement C1q) be prioritized as a therapeutic target for neurodege | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | While the study establishes P2RY12's role in VSMC foam cell formation in atheros | 0.62 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041434-d7920f3b |
| target_debate_target | Should CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1) be prioritized a | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should TFR1 (Transferrin receptor protein 1) be prioritized as a therapeutic tar | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should TGM2 (Protein-glutamine gamma-glutamyltransferase 2) be prioritized as a | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | While the abstract identifies AQP4 as a 'potential and promising target' and men | 0.76 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2 |
| target_debate_target | Should SIRT6 (Sirtuin-6) be prioritized as a therapeutic target for neurodegener | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should CX3CR1 (C-X3-C Motif Chemokine Receptor 1) be prioritized as a therapeuti | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | The circadian hypothesis assumes metabolic switching drives microglial priming, | 0.66 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062033-839c3e2a |